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Background:  Apoptosis-related  molecules  may  contribute  to left ventricular  (LV)  remodeling  after
myocardial  infarction  (MI). To  validate  this  hypothesis,  we  evaluated  the relation  between  circulating
plasma  levels  of  soluble  Fas  ligand  (sFas-L)  and  LV  remodeling  in patients  post-MI.
Methods  and  results:  This  prospective  multicenter  study  included  246  patients  with  a  ﬁrst  anterior  Q-
wave  MI. Serial  echocardiographic  studies  were  performed  at hospital  discharge  and  3 and  12  months
after  MI; quantitative  analysis  was  performed  at a core  echocardiography  laboratory.  Clinical  follow-up
was performed  at 3  years  post-MI.  Blood  samples  to measure  sFas-L  were  obtained  at 1 month  after  MI.
Median  sFas-L  level  was  50.2  pg/mL.  During  the  1 year  follow-up,  LV remodeling  was documented  by  a
signiﬁcant  increase  in  LV volumes.  LV  end-diastolic  and  end-systolic  volumes  at  baseline,  3  months,  and
12 months  after  MI  did  not  differ  according  to sFas-L  levels;  changes  in  LV  volumes  were  not  associated
with  sFas-L  levels.  By multivariate  analysis,  2 variables  were  independently  associated  with  LV  remod-
eling:  B-type  natriuretic  peptide  (BNP)  (p = 0.008)  and baseline  ejection  fraction  (p  = 0.02).  sFas-L  levels
were  not  associated  with  cardiovascular  death  or rehospitalization  for heart  failure  at  3 years;  conversely,
high levels  of  BNP  were  associated  with  worse  clinical  outcome.
Conclusions:  Soluble  Fas-L  levels  are  not  associated  with  LV remodeling  after  MI.  Further  research  is
needed to identify  apoptotic  markers  that may  be  associated  with  outcome  post-MI.
© 2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.ntroduction
Left ventricular (LV) remodeling – i.e. progressive LV dilation –
emains a signiﬁcant clinical problem in the modern era of myocar-
ial infarction (MI) management, despite the high rate of acute
eperfusion and widespread prescription of antiremodeling medi-
ation [1].  LV remodeling has been related to proteolytic activation,
ypertrophy, ﬁbrosis, and apoptosis [2–4].
Predicting LV remodeling is difﬁcult, even though several
isk factors have been identiﬁed such as infarct size [5].  Sev-
ral circulating biomarkers have been studied in relation to LV
emodeling [6–10]; however, for the time being, the most estab-
ished biomarker for LV remodeling is B-type natriuretic peptide
BNP) [11,12]. Taking into account the different biologic path-
ays implicated in LV remodeling after MI,  we hypothesized that
poptosis-related molecules may  contribute to the process by
∗ Corresponding author at: Hôpital Cardiologique, CHRU de Lille, Boul. Prof.
eclercq, 59037 Lille Cedex, France. Tel.: +33 320445045; fax: +33 320446652.
E-mail address: cbauters@chru-lille.fr (C. Bauters).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.03.001inducing apoptosis. Apoptotic cardiomyocytes have been reported
to be present at high levels in the infarct border zone [13]. Loss
of cardiomyocytes directly contributes to contractile dysfunction
[14] and myocyte apoptosis has been hypothesized to be a causal
mechanism of heart failure [15].
In the present study, we  focused on the role of soluble Fas ligand
(sFas-L) – a soluble form of Fas-L that can be detected in the circu-
lation – in LV remodeling after MI.  The Fas ligand is a cytokine that
mediates apoptosis [16]. Fas/Fas-L interaction plays a critical role
for granulation tissue cell apoptosis after MI  [17] and the behav-
ior of sFas-L is considered to reﬂect the status of activation of the
Fas/Fas-L system in heart failure [18]. Two studies have evaluated
the relation of sFas-L with LV remodeling after MI  [19,20]; however,
the results of these studies which were performed in a limited num-
ber of patients were discordant. sFas-L levels measured in a stable
state at distance from the acute event, might be a better indicator of
apoptosis; this has been supported by studies in stable hemodialy-
sis patients [21]. Our aim was therefore to investigate the relation of
circulating levels of sFas-L at 1 month after MI  with LV remodeling
in the REVE-2 study, a prospective study dedicated to biomarkers
of LV remodeling after a ﬁrst anterior MI.
vier Ltd. All rights reserved.
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ethods
tudy population
The design and inclusion and exclusion criteria of the REVE-2
tudy have been published in detail elsewhere [12]. Brieﬂy, it was  a
rospective multicenter study intended to analyze the association
f circulating biomarkers with LV remodeling [22]. We  enrolled
atients with a ﬁrst anterior wall Q-wave MI  from February 2006
hrough September 2008. Inclusion criteria were hospitalization
ithin 24 h after symptom onset and a predischarge echocar-
iogram showing at least 3 akinetic LV segments in the infarct
one. Exclusion criteria were inadequate quality of the echographic
mage, life-limiting noncardiac disease, signiﬁcant valvular disease,
r a prior Q-wave MI.  The Ethics Committee of the Center Hospi-
alier et Universitaire de Lille approved the research protocol, and
ach patient provided written informed consent.
chocardiographic studies
The protocol required serial echocardiographic studies at hospi-
al discharge (day 3–7), and at 3 and 12 months after MI.  A standard
chocardiographic imaging protocol was used, with apical 4- and
-chamber views; 2D echocardiograms of the LV short axis were
ecorded from the left parasternal region at 3 levels: the mitral
alve, mid-papillary muscle, and apex. All echocardiograms were
nalyzed at the Lille Core Echo Laboratory (Lille, France), as previ-
usly described [1]. LV end-diastolic volume (EDV) and end-systolic
olume (ESV), and ejection fraction (EF) were calculated with a
odiﬁed monoplane Simpson’s rule.
easurements of circulating biomarkers
Biomarkers were measured in plasma samples obtained at
 month after MI.  sFas-L was measured by an enzyme-linked
mmunoassay (R&D Systems, Minneapolis, MN,  USA). The pre-
ision of this assay is 4.1–5.4%. The mean detection limit was
.66 pg/mL. BNP was measured with a fully automated 2-site sand-
ich immunoassay on an Advia Centaur (Siemens Diagnostic,
urich, Switzerland). The lowest concentration measurable with
able 1
aseline characteristics of the study population.
All patients (n = 205) 1st tertile sFas
<40.2 pg/mL (n
Age (years) 56.5 ± 13.7 56.5 ± 11.6 
Women 42 (20%) 12 (18%) 
Hypertension 75 (37%) 25 (37%) 
Current smokers 100 (49%) 39 (57%) 
Diabetes mellitus 37 (18%) 13 (19%) 
Initial  reperfusion
Primary PCI 105 (51%) 36 (53%) 
Thrombolysis 75 (37%) 26 (38%) 
No  reperfusion 25 (12%) 6 (9%) 
Multivessel disease 77 (39%) 28 (43%) 
PCI  during hospitalization 175 (85%) 55 (81%) 
Killip  class ≥ 2 65 (32%) 24 (35%) 
Peak  CK (IQR) 2282 (2586) 2345 (2561) 
Medications at discharge
Aspirin 203 (99%) 68 (100%) 
Clopidogrel 198 (97%) 64 (94%) 
  Blockers 200 (98%) 65 (96%) 
ACE  inhibitors 199 (97%) 65 (96%) 
Aldosterone antagonists 69 (34%) 19 (28%) 
Diuretics 48 (23%) 16 (24%) 
Statins 192 (94%) 68 (100%) 
Fas-L: soluble Fas ligand; PCI: percutaneous coronary intervention; CK: creatine kinase;iology 60 (2012) 93–97
this assay with a ≤20% coefﬁcient of variation is 2.5 pg/mL. The
precision of this technique is 2.3–4.7%.
Clinical follow-up
Clinical follow-up was  performed at outpatient visits or by con-
tacting the general practitioner or cardiologist between February
2009 and June 2011. We collected data on death, and hospitaliza-
tion for heart failure (symptoms of dyspnea or edema associated
with bilateral rales, elevated venous pressure, or interstitial or alve-
olar edema on chest X-ray, or the addition of intravenous diuretics
or inotropic medications).
Statistical analysis
Stata 9.0 software was  used for statistical analysis. Results
are presented as the mean ± SD, median with interquartile range
(IQR), or as frequency, expressed as a percentage. Variables with
skewed distribution were log-transformed before use as contin-
uous variables in statistical analyses. Continuous variables were
compared with ANOVA or with simple linear regression, as appro-
priate. Discrete variables were compared using chi-square analysis
or the Fisher’s exact test as appropriate. Independent correlates
of changes in EDV were identiﬁed by multiple linear regression.
Variables signiﬁcant in univariate analysis at a p-level of 0.10 were
entered in the multivariate model. Colinearity was excluded by
means of a correlation matrix between candidate predictors. Cumu-
lative survival was estimated using the Kaplan–Meier method, and
the differences in survival curves were compared with a log rank
test. A p-value <0.05 was considered statistically signiﬁcant.
Results
A total of 246 patients were included in the REVE-2 study. One-
year echocardiographic follow-up was achieved in 226 patients;
among these, sFas-L levels 1 month after MI  were determined in
205 patients who  are the subject of the present report. The char-
acteristics of the 205 patients are summarized in Table 1. They had
a mean age of 56.5 ± 13.7 years and most (n = 163) were men. The
index MI  was  the ﬁrst manifestation of coronary artery disease in
most cases. Initial reperfusion therapy was  primary percutaneous
-L
 = 68)
2nd tertile sFas-L
40.2–60.2 pg/mL (n = 68)
3rd tertile sFas-L
>60.2 pg/mL (n = 69)
57.0 ± 13.8 56.1 ± 15.4
12 (18%) 18 (26%)
25 (37%) 25 (36%)
35 (51%) 26 (38%)
13 (19%) 11 (16%)
40 (59%) 29 (42%)
19 (28%) 30 (44%)
9 (13%) 10 (14%)
26 (40%) 23 (34%)
60 (90%) 60 (88%)
20 (29%) 21 (30%)
2252 (2460) 2282 (2647)
67 (99%) 68 (99%)
66 (97%) 68 (99%)
67 (99%) 68 (99%)
67 (99%) 67 (97%)
25 (37%) 25 (36%)
16 (24%) 16 (23%)
62 (91%) 62 (90%)
 IQR: interquartile range; ACE: angiotensin-converting enzyme.
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Table  2
Echocardiographic variables according to soluble Fas ligand levels.
1st tertile 2nd tertile 3rd tertile
End-diastolic volume, mL/m2
Baseline 53.8 ± 16.2 51.4 ± 11.0 52.5 ± 19.9
3  months 62.1 ± 18.0 59.4 ± 14.9 57.6 ± 16.6
1  year 64.9 ± 20.1 61.7 ± 16.8 60.6 ± 17.8
End-systolic volume, mL/m2
Baseline 27.7 ± 13.6 25.8 ± 7.8 26.9 ± 9.5
3  months 29.9 ± 13.1 27.8 ± 10.6 26.8 ± 11.0
1  year 30.8 ± 16.6 28.1 ± 12.2 27.8 ± 13.7
Ejection fraction, %
Baseline 49.5 ± 9.9 49.9 ± 8.4 49.4 ± 6.9
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Table 3
Multivariate linear model of change in end-diastolic volume from baseline to 1 year
follow-up.
Variables Multivariate beta coefﬁcient p-Value
BNP at 1 month 0.192 0.008
LVEF at baseline −0.172 0.02
Peak CK 0.143 0.058
sFas-L at 1 month −0.096 0.161
Killip class ≥ 2 0.020 0.795
architectural rearrangement of the extracellular matrix, inﬂamma-
tion, and cardiomyocyte loss due to necrosis or apoptosis [2–4,23].
The Fas ligand is a cytokine that mediates apoptosis by binding to its
receptor, Fas [16]. In humans, a soluble form of Fas-L (sFas-L) can3  months 53.0 ± 9.4 53.9 ± 9.1 54.5 ± 9.0
1  year 54.5 ± 10.6 55.8 ± 9.4 55.0 ± 9.8
oronary intervention (PCI) in 105 patients; the intervention was
uccessful [thrombolysis in myocardial infarction (TIMI) grade 3
ow in the culprit vessel] in 95 patients. Thrombolysis was  per-
ormed as the initial reperfusion strategy in 75 patients; 51 of
hose patients underwent rescue PCI with a procedural success
TIMI grade ﬂow 3) in 44 patients; routine coronary angiography
as performed during hospitalization in 21 of the 24 remaining
atients documenting a success of thrombolysis (TIMI grade 3 ﬂow)
n 17 patients. Finally, 25 patients did not undergo any reperfusion
herapy. In all, 180 patients (88%) underwent reperfusion ther-
py, and 156 patients (76%) patients underwent reperfusion with
ocumented angiographic success. Nearly all patients received sec-
ndary preventive treatment.
Median sFas-L levels determined 1 month after MI  were
0.2 pg/mL (IQR: 32.7). At the same timepoint, median BNP lev-
ls were 85 pg/mL (IQR: 135). Of note, there was  no correlation
etween sFas-L levels and BNP levels (r = −0.073; p = 0.301). The
aseline characteristics of the patients were studied accord-
ng to tertiles of sFas-L (1st tertile: <40.2 pg/mL, 2nd tertile:
0.2–60.2 pg/mL, 3rd tertile: >60.2 pg/mL). As shown in Table 1, the
aseline characteristics of the patients and the medications used
id not differ according to sFas-L levels.
During the 1 year follow-up, LV remodeling was documented
y a signiﬁcant increase in LVEDV (from 52.5 ± 13.8 mL/m2 to
2.4 ± 18.3 mL/m2; p < 0.0001) and LVESV (from 26.8 ± 10.5 mL/m2
o 28.9 ± 14.3 mL/m2; p = 0.0028). Median percent change in LVEDV
rom baseline to 1 year was +14%, and median percent change in
VESV was + 3%; these changes were similar in the 156 patients
ith successful reperfusion and in the 49 patients without suc-
essful reperfusion (p = 0.199 and 0.191, respectively). Recovery of
V systolic function was demonstrated by a signiﬁcant increase in
VEF (from 49.6 ± 8.4% to 55.4 ± 9.9%; p < 0.0001). Table 2 shows
VEDV, LVESV, and LVEF during the follow-up period according to
ertiles of sFas-L. The echocardiographic parameters did not dif-
er according to sFas-L levels. There was no signiﬁcant association
etween sFas-L levels and percent change in LVEDV (r = −0.107,
 = 0.126) or percent change in LVESV (r = −0.128, p = 0.07). Sim-
lar results were found when the analysis was  restricted to the
56 patients with successful reperfusion, or to the 95 patients with
uccessful PCI. A subgroup analysis was performed to investigate
hether sFas-L levels may  be associated with LV remodeling in
atients with low, intermediate, or high levels of BNP; changes in
DV did not differ according to sFas-L levels in any of the BNP ter-
iles (data not shown). Finally, multivariate analysis was  performed
o determine independent predictors of percent change in LVEDV.
s shown in Table 3, two variables were independently associated
ith LV remodeling: BNP at 1 month (positive association), and
aseline LVEF (negative association). The levels of sFas-L were not
ssociated with LV remodeling in this model (p = 0.161).
Clinical follow-up data were obtained for the 205 patients at a
edian of 1098 days. Kaplan–Meier curves for cardiovascular deathBNP: B-type natriuetic peptide; LVEF: left ventricular ejection fraction; CK: creatine
kinase; sFas-L: soluble Fas ligand.
or hospitalization for heart failure are shown in Fig. 1. Event-free
survival did not differ according to 1 month sFas-L tertiles (Fig. 1A);
by contrast, BNP levels were associated with clinical outcome:
patients in the higher BNP tertile had an increased risk of cardio-
vascular death or hospitalization for heart failure (p = 0.0018).
Discussion
LV remodeling has been related to various processes such asFig. 1. Kaplan–Meier survival curves according to soluble Fas ligand (sFas-L) (A) and
B-type natriuretic peptide (BNP) (B) tertiles at 1 month.
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e detected in the circulation. Elevated circulating levels of sFas-
 have been reported after MI  [19,24], and are believed to reﬂect
n activation of the Fas/Fas-L system in this setting. It has been
herefore hypothesized that the level of sFas-L after MI  may  be an
ndicator of the degree of LV remodeling. This has been addressed in
wo previous studies with discordant results: while Soeki et al. [19]
eported that sFas-L concentrations at 2 and 3 weeks after MI  were
igher in patients with important LV remodeling, no such relation
as observed in the study by Kondo et al. [20].
The results of the present study demonstrate that circulating
evels of sFas-L are not associated with LV remodeling. The concen-
ration of sFas-L was not associated with LVEDV, LVESV, or LVEF
hroughout the follow-up period; sFas-L levels were not associated
ith changes in LV volumes in univariate as well as in multivariate
nalyses. One strength of our results is the considerable number of
atients included for such a study on LV remodeling; in comparison,
he studies by Soeki et al. [19] and Kondo et al. [20] were performed
n 52 and 33 patients, respectively. Moreover, the fact that BNP was
ndependently associated with the changes in LVEDV demonstrates
hat our study had adequate power for detecting an association of
 biomarker with LV remodeling. The timing for biomarker mea-
urements (one month post-MI) was chosen to be at distance of MI
nd of the inﬂammatory process; we have recently shown that at
his time, C-reactive protein levels return to normal values with no
ssociation with LV remodeling [12]. Although we cannot exclude
hat a different timing may  have provided different results, it must
e mentioned that, in the study by Soeki et al. [19], the positive asso-
iation of sFas-L with LV remodeling was observed at a very similar
ime point (3 weeks). Of note, our results did not change when the
nalysis was restricted to patients with successful reperfusion, as
n the study by Soeki et al. [19].
Our results do not rule out an important role for apoptosis in
V remodeling. It can be hypothesized that we did not measure
he good target. There have been few studies on the associa-
ion of other cytokines with LV remodeling and the numbers of
atients included were again limited. While granzyme B [20] and
diponectin [25] were signiﬁcantly associated with LV remodel-
ng, tumor necrosis factor-alpha [20] and interleukin-6 [26] were
ot. Caspase-3 is difﬁcult to measure in circulating ﬂuids as most
f the assays are adapted for living cells or tissues. Apoptotic cell-
erived microparticles can be modulated in patients with cardiac
iseases [27], but simple assays for large number of patients are
ot readily available. Finally, molecular imaging methods, using
9mTc-labeled annexin A5 appears as a promising non invasive
pproach to detect apoptosis that may  offer prognostic information
28], but its implementation in multicentric studies on LV remod-
ling would be difﬁcult.
We used echocardiography to assess LV remodeling. Currently,
ardiac magnetic resonance imaging has been associated with
ower variability and appears as the best technique for LV remodel-
ng assessment [29]. Echocardiography, however, due to its greater
vailability and to technological advances, is also an appropriate
ption, especially when multicenter recruitment is considered.
linical implications – conclusion
In addition to pathophysiological insights, the association of a
iomarker with LV remodeling may  help to reﬁne risk stratiﬁcation
fter MI.  Indeed, LV remodeling indicates a high risk of heart fail-
re and death [30]. Since LV remodeling itself is difﬁcult to predict
n clinical practice, new prognostic indicators could allow a bet-
er selection of high-risk patients who in turn may  receive more
ggressive therapy and more frequent follow-up after MI.
[iology 60 (2012) 93–97
Our results do not support a role for sFas-L determination in
this context; further research is needed to identify new circulating
markers that may  be helpful on top of BNP to predict LV remodeling.
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